Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin by Carroll, Jeffrey B et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Potent and selective antisense oligonucleotides targeting single-nucleotide
polymorphisms in the Huntington disease gene / allele-specific silencing of mutant
huntingtin
Carroll, Jeffrey B; Warby, Simon C; Southwell, Amber L; Doty, Crystal N; Greenlee, Sarah;
Skotte, Niels; Hung, Gene; Bennett, C Frank; Freier, Susan M; Hayden, Michael R
Published in:
Molecular therapy : the journal of the American Society of Gene Therapy
DOI:
10.1038/mt.2011.201
Publication date:
2011
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., ... Hayden, M. R. (2011).
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington
disease gene / allele-specific silencing of mutant huntingtin. Molecular therapy : the journal of the American
Society of Gene Therapy, 19(12), 2178-85. https://doi.org/10.1038/mt.2011.201
Download date: 03. Feb. 2020
original article
2178 www.moleculartherapy.org  vol. 19 no. 12, 2178–2185 dec. 2011 
© The American Society of Gene & Cell Therapy
Huntington disease (HD) is an autosomal dominant neu-
rodegenerative disorder caused by CAG-expansion in 
the huntingtin gene (HTT) that results in a toxic gain 
of function in the mutant huntingtin protein (mHTT). 
Reducing the expression of mHTT is therefore an attrac-
tive therapy for HD. However, wild-type HTT protein is 
essential for development and has critical roles in main-
taining neuronal health. Therapies for HD that reduce 
wild-type HTT may therefore generate unintended nega-
tive consequences. We have identiﬁed single-nucleotide 
polymorphism (SNP) targets in the human HD popula-
tion for the disease-speciﬁc targeting of the HTT gene. 
Using primary cells from patients with HD and the trans-
genic YAC18 and BACHD mouse lines, we developed 
antisense oligonucleotide (ASO) molecules that potently 
and selectively silence mHTT at both exonic and intronic 
SNP sites. Modiﬁcation of these ASOs with S-constrained-
ethyl (cET) motifs signiﬁcantly improves potency while 
maintaining allele selectively in vitro. The developed ASO 
is potent and selective for mHTT in vivo after delivery to 
the mouse brain. We demonstrate that potent and selec-
tive allele-speciﬁc knockdown of the mHTT protein can 
be achieved at therapeutically relevant SNP sites using 
ASOs in vitro and in vivo.
Received 25 May 2011; accepted 24 August 2011; published online  
04 October 2011. doi:10.1038/mt.2011.201
INTRODUCTION
Unlike neurodegenerative diseases such as Alzheimer’s or 
Parkinson’s disease that are primarily idiopathic, every case 
of Huntington disease (HD) is associated with an expanded 
CAG-tract in the HTT gene.1 In theory, the identification of this 
specific mutation allows for neuroprotective therapies in pres-
ymptomatic HD mutation carriers. However, therapies currently 
available to patients with HD only offer moderate symptom relief 
and have no effect on disease progression.2,3
The large number of proposed disease mechanisms in HD has 
hindered development of disease-modifying therapies. HTT is a 
340-kDa protein that associates with many molecular partners 
including proteins, lipids, DNA, and mRNA.4 Wild-type HTT 
plays roles in critical processes including transcription, apoptosis, 
ER stress signaling, calcium homeostasis, axonal transport, endo-
cytosis, and synaptic transmission.4 Mutant huntingtin protein 
(mHTT) leads to altered proteolysis, transcriptional dysregula-
tion, altered intracellular trafficking, impaired metabolism, dys-
regulated calcium signaling, and altered synaptic activity.4 A wide 
variety of therapies aimed at these downstream events have been 
investigated, but results of these trials often show only modest 
benefit in mice and as yet no benefit in humans.
There is encouraging in vivo evidence that the reduction of 
HTT levels could be an effective therapy for human HD. The sever-
ity of signs and symptoms of HD in humans and mice is linked to 
mHTT expression5, and the postnatal reduction of HTT expres-
sion improves features of HD in transgenic mouse models.6–11 
There are several distinct strategies being pursued to lower cellular 
levels of HTT including viral delivery of siRNA6,10,12 or miRNA,13 
and small molecules.14,15 Preliminary short-term experiments sug-
gest that decreasing both wild type and mHTT in the brain is tol-
erated and produces a clinical benefit in mouse models.
However, there are also lines of evidence to suggest that loss 
of wild-type HTT function has detrimental consequences. HTT 
is essential for embryogenesis; total excision of hdh causes loss of 
viability in early embryonic stages while reduction of hdh to ~33% 
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results in perinatal lethality and altered neurodevelopment.16,17 
Complete loss of HTT could lead to dysregulation of many cel-
lular processes that are important to the ongoing health of neu-
rons in adulthood, given its known roles in negatively regulating 
apoptosis and transcription of prosurvival genes.4,18–22 Many pre-
vious models of in vivo HTT silencing have reduced mHTT but 
maintained a partial or complete complement of wild-type Hdh, 
confounding our understanding of the relative importance of loss 
of HTT function in HD.6–10 However, it is clear that the complete 
inactivation of wild-type Hdh in the forebrain of mice postnatally 
causes neurodegeneration.23
Considering that neuroprotective therapies for HD will likely 
begin in early adulthood and continue throughout life, exam-
ining the potential for the allele-specific reduction of mHTT is 
prudent.24–31 Allele-specific silencing of HTT may be possible, 
either by targeting the expanded CAG-tract directly30,32 or by tar-
geting genetic polymorphisms linked to CAG-expansion.28,33
Short synthetic antisense oligonucleotides (ASOs) silence 
gene expression post-transcriptionally by several mechanisms34 
and can discriminate between single-nucleotide polymorphism 
(SNP) alleles at targeted sites.35 ASOs have been successfully used 
in the central nervous system (CNS) of rodents, nonhuman pri-
mates, and human patients with cytomegalovirus (CMV) retinitis 
and are being investigated for motor neuron diseases following 
intrathecal administration.36 They are therefore a viable option 
for allele-specific therapeutics in HD. Relative to viral delivery 
of siRNA, ASOs provide substantial benefits. Most importantly 
for allele-specific approaches, ASOs can target SNPs anywhere in 
the pre-mRNA, including introns, and therefore the number of 
potential SNP targets is extensive. Only 8% of the validated SNPs 
in the HTT pre-mRNA are coding, and therefore the number of 
targets accessible to siRNA is smaller (Supplementary Table S2). 
ASOs can also be effectively delivered to multiple cell types, 
including astrocytes and neurons, throughout the adult primate 
CNS via intracerebroventricular or intrathecal infusion.36 Because 
ASO delivery to the adult primate CNS can be achieved by simple 
infusion, viral delivery is not required and ASO dosing can be pre-
cisely controlled or stopped as needed. Based on these advantages, 
we have chosen to investigate the use of ASOs to target and silence 
SNP alleles of mutant HTT mRNA.
RESULTS
SNP identiﬁcation and genotyping
Using a custom SNP genotyping assay (“96SNP panel”), we ana-
lyzed 234 patients with HD at 91 SNP locations in the HTT gene 
(Supplementary Table S1). We have previously described 22 
of these SNPs in a subset of these patients, genotyped using the 
SNPstream assay.33 After using family trio information to phase 
the SNP alleles to the CAG-tract size of each chromosome, we 
found that 50/91 SNPs are enriched on HD chromosomes (>36 
CAG repeats) relative to control chromosomes (<27CAG repeats) 
(Bonferroni-corrected chi-squared P < 0.00055). The targets of 
allele-specific silencing are heterozygous SNPs, which allow spar-
ing of the wild-type allele. Of the potential SNP targets, 41 alleles 
are individually heterozygous in greater than 30% of the sequenced 
HD population (Figure 1). Combinatorial analysis suggests that a 
panel of as few as three of these alleles, successfully targeted, could 
provide coverage for up to 85% of the HD population.28,33
ASO development pipeline and human 
ﬁbroblast genotyping
In order to facilitate the identification, screening and optimization 
of therapeutics against disease-specific SNP targets, we describe 
the pipeline we have used for ASO development (Supplementary 
Figure S1). We propose that this pipeline will be useful for the 
continued development of therapeutic approaches in HD, and the 
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Figure 1 Identiﬁcation of SNP alleles that are associated with HD chromosomes and can be used for allele-speciﬁc targeting in HD. A SNP 
allele was deﬁned as a disease allele if it is signiﬁcantly more common on HD than control chromosomes. In a population of 234 Caucasian patients 
with HD, we identify 50 SNPs with disease alleles (chi-squared, Bonferroni-corrected P value P < 0.00055) and present the heterozygosity rate for 
the disease allele in patients with HD (percentage heterozygosity in italics). The best targets for allele-speciﬁc therapy will be speciﬁc SNP alleles 
that maximize both the frequency on HD chromosomes and heterozygosity in patients with HD. HD, Huntington disease; SNP, single-nucleotide 
polymorphism.
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methods useful for the allele-specific targeting of other dominant 
diseases using ASO or other silencing technology.
We began our screening with the list of SNPs enriched in the 
target population identified above. We then obtained a number of 
publically available primary human fibroblast cell lines from the 
Coriell repository (http://www.coriell.org/). Cell lines were cho-
sen for which sufficient family information was available to enable 
successful phasing of genotyping results. The cell lines were geno-
typed using our 96SNP panel assay (Supplementary Table S3). 
Cell lines homozygous for a target SNP allele are considered “on 
target” because both HTT alleles are completely complementary to 
ASOs targeting the SNP. Cell lines homozygous for the nontarget 
allele are “off target” because neither HTT allele is perfectly tar-
geted by SNP-targeted ASOs. This “on/off target” approach allows 
us to perform our primary potency screen as a counter screen 
in primary cells, with endogenous levels of genetically accurate 
target transcript. This approach of using homozygous on/off tar-
get cell lines also avoids the need to quantify huntingtin alleles 
separately, which is possible but technically demanding for a large 
number of SNP targets.
Potency and selectivity: human ﬁbroblasts
Following identification of SNP targets and cell lines with the 
appropriate genotypes, we synthesized ASOs targeting SNP alleles 
and screened them for potency and selectivity. For initial screening, 
the ASOs used were phosphorothioate substituted 19-mers con-
taining five 2’-O-methoxy-ethyl ribose sugars in each wing and a 
string of nine DNA residues in the gap (“5-9-5 2’-O- Methoxyethyl 
(MOE) gapmers”). These ASOs bind to target RNA and support 
cleavage by RNase H of target RNA opposite the DNA gap. Data 
shown are from ASOs with the target SNP positioned opposite the 
DNA gap.37 A potent non-allele-specific positive control 5-10-5 
MOE gapmer was tested in each experiment (“non-allele-specific 
positive control”).
ASOs were screened for activity at a single dose in “on target” 
cell lines, to enable direct comparisons to non-allele-specific pos-
itive control. This primary screen identified a number of ASOs 
that effectively reduce HTT mRNA (Figure 2a). ASOs whose 
silencing was not superior to off target negative control ASOs 
were discarded at this step. We next counter-screened ASOs at 
a single dose in “off target” cell lines homozygous for the non-
targeted allele. Potency of HTT mRNA knockdown in on versus 
off target cell lines is summarized in Figure 2b for those ASOs 
that silence HTT more effectively in on target cell lines than off 
target cell lines. Given these results, 19 ASOs targeting 14 alleles 
were chosen for detailed dose–response studies of HTT mRNA 
knockdown in fibroblasts to confirm selectivity. Sample data for 
an allele-specific ASO targeting rs7685686_A in Figure 2c dem-
onstrate increased potency in on versus off target cell lines (left), 
while non-allele-specific positive control ASO is equally potent 
in both cell lines (right). These potency, selectivity, and dose–
response studies enabled the prioritization of ASOs. In prioritiz-
ing ASOs for protein silencing experiments, we also considered 
relative coverage of the HD patient population for the targeted 
SNP. We proceeded with validation of protein knockdown of 
ASOs targeting our top four ranked SNPs (rs7685686, rs4690072, 
rs2024115, and rs363088). This panel of four SNPs does not 
provide combinatorial advantage as they are all in high linkage 
disequilibrium with each other, but rather represents a panel of 
leads from which to select our top ASO.
Potency and selectivity: mouse neurons
Neurons are one of the primary cell types of interest for HD thera-
peutics, and ASOs effectively target neurons in the adult CNS.36 
Because neurons efficiently take up ASO in vivo, we considered 
the possibility that they might do so in vitro. We examined the 
response of murine primary cortical neurons in culture to ASO 
exposure in culture media. In neurons derived from YAC128 HD 
mice,38 a single application of nonallele-targeted positive control 
ASO reduces transgenic HTT protein expression in neurons, with 
a clear dose response (Figure 3a, left, IC50 = 27.0 nmol/l, 95% 
CI 22.7−32.2 nmol/l). We examined other full-length transgenic 
mouse models (the YAC1839 mice and BACHD40 mice) and found 
that ASO-induced silencing of transgenic htt was similar in both 
lines at 500 and 1,500 nmol/l Figure 3a, right). HTT silencing in 
primary neurons exposed to ASO is rapid (maximal by 5 days) 
and lasts for at least 20 days after a single treatment.
Genotyping transgenic HTT in YAC18 (wild type) and BACHD 
(CAG-expanded) mice using our 91SNP assay revealed genotype 
differences at a number of target SNP allele sites (Supplementary 
Table S2). Sequencing of target sites of interest verified that tar-
geted SNP alleles were the only genetic variation in the region 
targeted by ASOs. In the case of the top four ranked ASOs, the 
BACHD transgene shares target alleles with the majority of HD 
chromosomes, while the YAC18 transgene does not. This enabled 
us to establish a primary neuron counter screen in which human 
HTT knockdown was compared in paired cortical neuron cultures 
from YAC18 and BACHD neurons (Figure 3b). At 1.5 μmol/l 
ASO BACHD human HTT knockdown after treatment with 
allele- specific ASO varies between 39% (rs4690072, Figure 3b red 
line, t = 4.291, P < 0.01) and 68% (rs363088 Figure 3b red line, t = 
7.37, P < 0.001). None of the allele-specific ASOs tested signifi-
cantly reduced HTT levels in YAC18 neurons (Figure 3b, black 
lines), while treatment with non-allele-specific positive control 
ASO robustly reduced HTT levels (Figure 3a, right).
Structure activity relationship (SAR)
ASO modifications have been used to increase affinity and 
potency toward target mRNA, reduce in vivo toxicity, and 
improve pharmacokinetic and pharmacodynamic properties.34 
Modifications can be made to the backbone chemistry by alter-
ing either the backbone itself, or the base sugar moiety, generally 
at the 2’-position.34 In particular, a 2’–4’ constraint in the fura-
nose ring improves hybridization to target mRNA by enforcing 
a N-type sugar conformation.41 To improve potency of our lead 
ASOs, a high affinity bicyclic nucleoside41 S-constrained ethyl 
(cEt) was substituted in the 5’ and 3’ “wings” of ASOs targeting 
alleles of SNP rs7685686 (Figure 4a). cEt-modified ASOs were 
electroporated into human HD patient fibroblasts on target or 
off target for the disease allele (A) at SNP rs7685686. Addition of 
cEt motifs to wing sequences increased potency of ASOs toward 
HTT mRNA, while sparing selectivity for the targeted allele 
(Figure 4b, compare red and blue lines, MOE IC50 = 491 nmol/l, 
cEt IC50 = 93 nmol/l). Selectivity was spared as the ratio of IC50 in 
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on versus off cell lines remained similar between MOE and cEt 
ASOs (Figure 4b, IC50 ratio MOE = 10.7, cET = 9.5). We then 
examined the potency of a cEt-modified ASO in primary neu-
rons from the YAC18 and BACHD mice. cEt-modified ASO was 
more potent than the paired MOE at this SNP allele (Figure 4c, 
500 nmol/l ASO htt protein remaining = 45.3 ± 14.8% MOE, 
16.6 ± 5.6% cEt), while selectivity is maintained.
Potency and selectivity: in vivo
Because intracerebroventricular infusion of ASO into the murine 
CNS has been shown lead to transgene silencing,36 we consid-
ered the possibility that intraparenchymal bolus delivery of ASO 
directly to the striatum of mice would lead to effective silencing. 
Using BACHD and YAC18 mice, which express the A and T alleles 
of rs7685686, respectively, allows us to examine allele specificity 
in a manner analogous to our primary neuron counter screen 
(Figures 3 and 4).
Adult mice were injected with either vehicle or 50 μg of non-
allele-specific ASO that inhibits mouse and human HTT expres-
sion or allele-specific MOE ASO targeting rs7685686_A. To 
examine potential toxic effects resulting from the use of ASOs in 
the CNS, we examined gliosis in injected striata using an antibody 
reactive to glial fibrillary acidic protein (GFAP) and a novel anti-
body reactive to the chemical backbone of the ASO molecule. The 
ASO-reactive antibody shows clear immunoreactivity in injected 
striata, while sham-treated mice do not (Figure 5a). DARPP-32, a 
striatally enriched gene, shows strong immunoreactivity in striata, 
confirming that the injected ASO is being delivered to the striatum 
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(Figure 5a). Staining with GFAP-reactive antibodies reveals mild 
gliosis immediately proximal to the injection site in both sham- 
and ASO-injected animals, which is not qualitatively worse in the 
ASO-injected animals (Figure 5a).
Western blots from injected striata demonstrate that non-
 allele-specific positive control ASO silence transgenic human 
HTT in both YAC18 and BACHD mice (Figure 5b, YAC18: 
19.23 ± 2.77 % HTT remaining; BACHD: 17.44 ± 1.75 % HTT 
remaining). Human allele-specific ASO targeting rs7685686_A 
is potent against human transgenic HTT in BACHD, but not 
YAC18 mice (Figure 5a, YAC18: 96.69 ± 13.33 % HTT remaining; 
BACHD: 47.44 ± 4.61 % HTT remaining; Bonferroni post-test t = 
8.4; P < 0.0001).
DISCUSSION
We have identified 50 viable SNP targets in the human HTT gene 
(Figure 1) and established a unique set of tools and strategies to 
develop SNP-targeted ASOs that potently and selectively silence 
mHTT. This allele-specific targeting pipeline (Supplementary 
Figure S1) allows for the rapid prioritization of allele-specific 
compounds based on potency, selectivity, and population coverage 
for patients with HD. The pipeline uses genotyped and phased HD 
patient fibroblasts and two lines of transgenic HD mice with dif-
ferent human HD haplotypes to efficiently identify allele- specific 
lead compounds.
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Figure 3 Development and use of a primary cortical neuron coun-
ter screen utilizing YAC and BACHD transgenic mice. (a) Left—
Development of primary neuron assay in cortical neurons from the YAC128 
mice. Bath application at DIV 2 with a non-allele-speciﬁc positive control 
ASO leads to clear dose-dependent silencing of HTT (IC50 = 27.03 nmol/l, 
95% CI 22.66–32.24 nmol/l) after 6 days of treatment. Right—Treatment 
of primary cortical neurons from YAC18 and BACHD mice with 500 or 
1,500 nmol/l of non-allele-speciﬁc positive control ASO leads to potent 
reduction of transgenic human HTT, detected with a human HTT-speciﬁc 
antibody (N = 6 YAC18 cultures, 10 BACHD cultures; 2-way ANOVA geno-
type F(1,42) = 23.08, P < 0.0001; treatment F(1,42) = 1170, P < 0.0001; 
interaction F(1,42) = 6.2, P = 0.0042). (b) Paired primary cortical neu-
rons from YAC18 or BACHD mice were treated after 2 days in vitro with 
the indicated doses of ASO for 6 days and HTT detected with a human-
speciﬁc HTT antibody. ASOs targeting SNP alleles selectively knockdown 
BACHD, but not YAC18, HTT transgene. rs7685686: N = 6 YAC18 cul-
tures, 6 BACHD cultures; 2-way ANOVA genotype F(1,30) = 67.24, P < 
0.0001; treatment F(2,30) = 24.9, P < 0.0001; interaction F(2,30) = 17.5, 
P<0.0001. rs4690072: N = 6 YAC18 cultures, 5 BACHD cultures; 2-way 
ANOVA genotype F(1,24) = 29.6, P < 0.0001; treatment F(2,24) = 18.3, 
P < 0.0001; interaction F(2,24) = 10.0, P<0.0001. rs2024115: N = 6 YAC18 
cultures, 4 BACHD cultures; 2-way ANOVA genotype F(1,33) = 66.2, P < 
0.0001; treatment F(2,33) = 7.5, P = 0.0021; interaction F(2,33) = 17.0, 
P<0.0001. rs363088: N = 6 YAC18 cultures, 4 BACHD cultures; 2-way 
ANOVA genotype F(1,24) = 62.3, P < 0.0001; treatment F(2,24) = 9.3, P = 
0.0010; interaction F(2,24) = 16.2, P<0.0001.(*, **** Represent Bonferroni 
multiple comparison P values of P < 0.05 and P < 0.0001, respectively).
b c
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Figure 4 An ASO with S-constrained ethyl motif (cET) backbone has 
increased potency and equivalent allele-selectivity to a traditional 
MOE backbone. (a) Motifs used in ASO backbones. (b) Dose–response 
curves for HTT silencing after electroporation of human HD ﬁbroblasts 
with MOE or cEt-modiﬁed ASOs targeting rs7685686_A. ASOs were, in 
each case, more potent toward HTT in cell lines homozygous for the 
targeted SNP allele versus homozygous for the untargeted allele. ASO 
potency is increased with no loss of speciﬁcity by addition of cEt motifs 
to wing structures, relative to 5-9-5 MOE design (IC50’s indicated). 
Error bars indicate range, and lines indicate ﬁt curves. (c) Veriﬁcation of 
increased potency and preserved speciﬁcity of cEt-modiﬁed ASOs target-
ing rs7685686_A (blue) toward HTT protein in BACHD neurons, relative 
to the equivalent MOE ASO (red). (Two-way ANOVA effect of ASO modi-
ﬁcation in BACHD neurons P < 0.0001. **, **** Represent Bonferroni 
multiple comparisons between MOE ASO and cET ASO P values of P < 
0.01 and P < 0.0001, respectively). ASO, antisense oligonucleotide; 
MOE, 2’-O-Methoxyethyl.
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Using this pipeline, we developed ASOs that specifically and 
potently reduce mHTT levels in primary human cells (Figure 2), 
cultured primary neurons (Figures 3 and 4), and the adult mouse 
CNS (Figure 5). The ASOs used in this study are clinically rele-
vant for the human HD population—ASOs with similar chemical 
composition have a proven track record in human clinical trials.42 
Furthermore, ASOs can be improved with backbone modifica-
tions, and we now demonstrate that these modifications result 
in improved potency without loss of allele specificity (Figure 4). 
Critically, the ASOs we have developed maintain potency and 
specificity after in vivo delivery, confirming their therapeutic rel-
evance (Figure 5).
Genetics and population coverage
Our primary goal in this study was to develop the most effective 
possible single ASO with high population coverage. Our ASOs 
targeting rs7685686_A, for example, could be used in 49% of the 
HD patient population (Figure 1). However, our genetic approach 
and large number of genotyped SNPs allows the discovery of 
targets that have combinatorial advantage to maximize relative 
coverage of the HD patient population.28,33 The efforts described 
here are the first step in an iterative process of building a panel 
of ASOs that provide allele-specific silencing to the majority of 
patients with HD. The specific ASO best suited to any one individ-
ual can be determined using SNP-CAG phasing methods recently 
described.43,44
ASO SAR
A major benefit of ASOs is the mature set of chemical tools for 
modulating ASO activities via structure activity relationship 
(SAR) studies. ASO modifications have been used to increase 
affinity and potency toward target mRNA, reduce in vivo toxic-
ity and improve pharmacokinetic/pharmacodynamic properties.34 
Modifications can be made to the backbone chemistry by altering 
either the backbone itself, or the base sugar moiety, generally at 
the 2’-position.34
We have primarily used chimeric MOE gapmer designs for the 
current study (Figures 2 and 3). In an attempt to improve potency 
while maintaining selectivity, we substituted a bicyclic nucleo-
side cEt in the wings of the ASO.41 This motif has been shown to 
increase affinity of ASOs to their target mRNAs, but it was unclear 
whether allele selectivity could be maintained. We find that cEt-
modified ASOs targeting rs7685686_A are fivefold more potent 
than the parental MOE ASO, while allele specificity is preserved 
(Figure 4). This suggests that significant improvements can be 
made to ASOs by manipulating backbone chemistry.
ASO potency in neurons in vitro and in vivo
The ultimate target of therapeutics for HD is the adult CNS, which 
is a notoriously difficult tissue compartment to access and treat.45 
We first tested our ASO compounds with cultured neurons and 
found that neurons efficiently absorb ASO from culture media 
without transfection reagents. This phenomenon will be valuable 
for future experiments using gene silencing in primary neurons.
Further, using adult YAC18 and BACHD mice, we demon-
strate that ASOs delivered to the striatum are potent, and selective 
for targeted alleles (Figure 5). The striatum is the most vulner-
able region of the brain in HD and is the likely first target of HTT 
silencing approaches in humans.46 The fact that we are able to 
selectively silence full-length transgenic HTT in the adult stria-
tum suggests that the ASOs we have developed are of direct thera-
peutic relevance.
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Figure 5 ASOs are potent and selective after acute delivery to the murine central nervous system (CNS). (a) YAC18 and BACHD mice were 
injected intrastriatally with PBS vehicle (sham) or 50 μg ASO (non-allele-speciﬁc positive control or allele-speciﬁc targeting rs7685686). Injected striata 
were examined with antibodies reactive to the ASO backbone, DARPP-32, and GFAP. ASO immunoreactivity is observed throughout the DARPP-32 
positive striatum in injected animals. GFAP immunoreactivity is limited proximally to the needle tract in both sham- and ASO-injected animals. 
(b) Transgenic HTT levels were examined by western blot 14 days post-injection. Both YAC18 and BACHD transgenes are reduced after injection with 
non-allele-speciﬁc ASO, while the ASO targeting rs7685686_A is only potent in the BACHD striatum (YAC18 versus BACHD Bonferroni post-test t = 
8.4, P < 0.0001). ASO, antisense oligonucleotide; GFAP, glial ﬁbrillary acidic protein; PBS, phosphate-buffered saline.
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Path to the clinic
We envision that leads developed here will be complemented by 
the development of additional ASOs providing more complete 
population coverage. A majority of the human HD population 
can be represented in a panel of as few as three SNP-targeting 
reagents.28,33 With such a panel of ASOs in hand, we foresee that 
patients would be genotyped at subject SNPs using a method that 
links the SNP genotypes to CAG-size.43,44 With these phased geno-
types, an ASO from the panel would be chosen to preferentially 
target mHTT in each patient.
Assuming the outlined allele-specific silencing approach is 
possible, the question remains whether it is preferable to non-
allele-specific HTT silencing. Available evidence23,47 indicates 
that HTT has vital roles in the mature CNS and that silencing 
both endogenous and mutant HTT is associated with significant 
transcriptional alterations.9,10 We speculate that mild phenotypes 
observed in mice living less than a year with partially reduced 
huntingtin levels may predict more severe complications in the 
human CNS after decades of treatment. This consideration argues 
for the most judicious and targeted approach possible to HTT 
silencing in humans. Following successful delivery and toxicity 
studies, allele-specific HTT ASOs represent such an option for the 
majority of the HD population.
MATERIALS AND METHODS
Genotyping. We designed a genotyping panel of 96 SNPs using a Goldengate 
assay on the Illumina BeadArray platform. The LD patterns of 900 SNPs 
known to exist in the htt region were compiled by gathering data from 
Hapmap, DBSNP, and direct sequencing of the htt region performed at the 
CMMT; 96 top priority SNPs were selected. The 96SNP assay provided geno-
typing information on 91 SNPs in the HTT gene region (5 SNPs failed qual-
ity control). The 96 SNP genotyping assay was performed on a total of 1,151 
different DNA samples from individuals in 390 different HD pedigrees. The 
genotyping results for each patient with HD were phased by incorporating 
genotype information of family trios into PHASE 2.0 software.
Ethics statement. DNA samples were taken from the Huntington Disease 
BioBank at the University of British Columbia. Consent and access pro-
cedures were in accordance with institutional ethics approval for human 
research (UBC certificate H05-70532).
ASO treatment in vitro. ASOs were transfected into fibroblasts by elec-
troporation using the Electro Square PoratorTM ECM 830 (BTX Harvard 
Apparatus). Cells were seeded in 96-well electroporation plates (2 mm) at 
2.5 × 105 cells/ml and electroporated (130 V, 6.9 ms). For neuronal treat-
ments, ASOs were resuspended in sterilized phosphate-buffered saline 
(PBS) to a concentration of 1–5 mmol/l and stock added to supplementary 
media on DIV2 to the indicated final concentration.
SNP sequencing in transgenic mice. SNP sequencing was performed in 
BACHD and YAC mice using the GoldenGate 96 SNP assay outlined above 
(see genotyping section). Several lines of both BAC HD and YAC HD mice 
were tested to confirm the results.
Primary neuron screen. YAC18 cultures were prepared as described48 from 
E16.5 pregnant female YAC18 mice. BACHD E16.5 embryos were iso-
lated from pregnant FVB WT mice bred with BACHD (+/−) male mice. 
Each 6-well culture plate consisted of two untreated wells, and two dupli-
cate ASO treatments. The quantification of transgenic HTT protein was 
performed using immunoblotting with an antibody (HD650) specific to 
human htt (amino acids 650–663 VLRDEATEPGDQEN),38 normalized to 
calnexin levels (Supplementary Materials and Methods).
ASO treatment in vivo. Mice were anesthetized with ketamine or 
 xylazine and placed in a stereotaxic frame. After shaving and disinfec-
tion of the scalp, an incision was made along the midline. A burr hole was 
made at 0.75 mm anterior and 2 mm lateral to Bregma, and 50 μg ASO 
in 4 μl total volume or sterile PBS vehicle was injected at a rate of 0.5 μl/
minute and a depth of 3.5 mm using a 5-μl Hamilton syringe. The needle 
was left in place for 5 minutes and slowly withdrawn. Mice were killed 14 
days post- injection and processed for immunohistochemistry or protein. 
For immunohistochemistry, brain tissue was fixed by perfusion of 4% 
paraformaldehyde in PBS. Brains were cut into 25-μm free-floating coro-
nal sections. Sections were blocked for 30 minutes in 3% bovine serum 
albumin, 10% normal goat serum, 0.1% Triton X-100 in PBS. Primary 
antibodies: rabbit anti-ASO (1:7500), rabbit anti-GFAP (1:1000 Dako, 
Carpinteria, CA), or rat anti-dopamine- and cyclic AMP-regulated phos-
phoprotein (DARPP-32) (1:1000 R&D Systems, Minneapolis, MN) were 
diluted in blocking solution and incubated on sections overnight at 4 °C. 
Secondary Alexa-fluro 488-conjugated goat anti-mouse or Alexa-fluor 
568 conjugated goat anti-rabbit antibodies (1:250 Invitrogen, Carlsbad, 
CA) were incubated on sections for 1.5 hours at room temperature. 
Sections were then mounted on slides with ProLong Gold antifade 
reagent with DAPI (Invitrogen). For protein analysis, lysates of fresh 
frozen injected striata were evaluated for YAC18 and BACHD Htt levels 
by immunoblotting with a human-specific HTT antibody, 2168 (1:1000 
Millipore, Billerica, MA) and normalization to calnexin (1:2500 Sigma, 
St. Louis, MO).
SUPPLEMENTARY MATERIAL
Figure S1. Flowchart diagramming the allele-speciﬁc targeting pipe-
line, with indicated number of target SNPs and ASO designs at each 
step.
Table S1. Phased allele frequencies in 234 human HD patients.
Table S2. Summary of the distribution of different classes of SNPs in 
the HTT coding region.
Table S3. SNP sequences at described sites in primary human ﬁbro-
blasts (Corriell).
Materials and Methods.
ACKNOWLEDGMENTS
William Yang kindly provided the BACHD mice. We thank C. Ross and 
C. Carter for their assistance with genotyping, as well as L. Lau, M. 
Wang, and N. Bissada for support with animal work. This work was 
supported by grants from the Canadian Institute for Health Research 
and Michael Smith Foundation (J.B.C. and S.C.W.). M.R.H. is a Killam 
University Professor and holds a Canada Research Chair. S.G., G.H., 
S.M.F., and C.F.B. are employees of, with a ﬁnancial interest in, Isis 
Pharmaceuticals. Isis pharmaceuticals synthesized and provided the 
ASOs used in this study, and supported work in the laboratory of 
M.R.H.
REFERENCES
1. The Huntington Disease Collaborative Research Group (1993). A novel gene 
containing a trinucleotide repeat that is expanded and unstable on Huntington’s 
disease chromosomes. Cell 72: 971–983.
2. The Huntington Study Group (2006). Tetrabenazine as antichorea therapy in 
Huntington disease: a randomized controlled trial. Neurology 66: 366–372.
3. De Marchi, N, Daniele, F and Ragone, MA (2001). Fluoxetine in the treatment of 
Huntington’s disease. Psychopharmacology (Berl) 153: 264–266.
4. Zuccato, C, Valenza, M and Cattaneo, E (2010). Molecular mechanisms and potential 
therapeutical targets in Huntington’s disease. Physiol Rev 90: 905–981.
5. Graham, RK, Slow, EJ, Deng, Y, Bissada, N, Lu, G, Pearson, J et al. (2006). Levels of 
mutant huntingtin inﬂuence the phenotypic severity of Huntington disease in YAC128 
mouse models. Neurobiol Dis 21: 444–455.
6. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA 
interference improves motor and neuropathological abnormalities in a Huntington’s 
disease mouse model. Proc Natl Acad Sci USA 102: 5820–5825.
7. Yamamoto, A, Lucas, JJ and Hen, R (2000). Reversal of neuropathology and motor 
dysfunction in a conditional model of Huntington’s disease. Cell 101: 57–66.
8. Rodriguez-Lebron, E, Denovan-Wright, EM, Nash, K, Lewin, AS and Mandel, RJ 
(2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial 
reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther 
12: 618–633.
Molecular Therapy  vol. 19 no. 12 dec. 2011 2185
© The American Society of Gene & Cell Therapy
Allele-Speciﬁc Silencing of Mutant Huntingtin
9. Drouet, V, Perrin, V, Hassig, R, Dufour, N, Auregan, G, Alves, S et al. (2009). 
Sustained effects of nonallele-speciﬁc Huntingtin silencing. Ann Neurol 65: 
276–285.
10. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). 
Nonallele-speciﬁc silencing of mutant and wild-type huntingtin demonstrates 
therapeutic efﬁcacy in Huntington’s disease mice. Mol Ther 17: 1053–1063.
11. Wang, YL, Liu, W, Wada, E, Murata, M, Wada, K and Kanazawa, I (2005). Clinico-
pathological rescue of a model mouse of Huntington’s disease by siRNA. Neurosci Res 
53: 241–249.
12. DiFiglia, M, Sena-Esteves, M, Chase, K, Sapp, E, Pﬁster, E, Sass, M et al. (2007). 
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and 
cortical neuropathology and behavioral deﬁcits. Proc Natl Acad Sci USA 104: 
17204–17209.
13. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. 
(2008). Artiﬁcial miRNAs mitigate shRNA-mediated toxicity in the brain: implications 
for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868–5873.
14. Sarkar, S, Perlstein, EO, Imarisio, S, Pineau, S, Cordenier, A, Maglathlin, RL et al. 
(2007). Small molecules enhance autophagy and reduce toxicity in Huntington’s 
disease models. Nat Chem Biol 3: 331–338.
15. Tsvetkov, AS, Miller, J, Arrasate, M, Wong, JS, Pleiss, MA and Finkbeiner, S (2010). A 
small-molecule scaffold induces autophagy in primary neurons and protects against 
toxicity in a Huntington disease model. Proc Natl Acad Sci USA 107: 16982–16987.
16. Nasir, J, Floresco, SB, O’Kusky, JR, Diewert, VM, Richman, JM, Zeisler, J et al. (1995). 
Targeted disruption of the Huntington’s disease gene results in embryonic lethality 
and behavioral and morphological changes in heterozygotes. Cell 81: 811–823.
17. White, JK, Auerbach, W, Duyao, MP, Vonsattel, JP, Gusella, JF, Joyner, AL et al. (1997). 
Huntingtin is required for neurogenesis and is not impaired by the Huntington’s 
disease CAG expansion. Nat Genet 17: 404–410.
18. Zhang, Y, Leavitt, BR, van Raamsdonk, JM, Dragatsis, I, Goldowitz, D, MacDonald, ME 
et al. (2006). Huntingtin inhibits caspase-3 activation. EMBO J 25: 5896–5906.
19. Leavitt, BR, van Raamsdonk, JM, Shehadeh, J, Fernandes, H, Murphy, Z, Graham, RK 
et al. (2006). Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 
96: 1121–1129.
20. Zuccato, C, Ciammola, A, Rigamonti, D, Leavitt, BR, Goffredo, D, Conti, L et al. 
(2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. 
Science 293: 493–498.
21. Leavitt, BR, Guttman, JA, Hodgson, JG, Kimel, GH, Singaraja, R, Vogl, AW et al. (2001). 
Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J 
Hum Genet 68: 313–324.
22. Rigamonti, D, Sipione, S, Goffredo, D, Zuccato, C, Fossale, E and Cattaneo, E (2001). 
Huntingtin’s neuroprotective activity occurs via inhibition of procaspase-9 processing. 
J Biol Chem 276: 14545–14548.
23. Dragatsis, I, Levine, MS and Zeitlin, S (2000). Inactivation of Hdh in the brain and 
testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26: 
300–306.
24. Rodriguez-Lebron, E and Paulson, HL (2006). Allele-speciﬁc RNA interference for 
neurological disease. Gene Ther 13: 576–581.
25. van Bilsen, PH, Jaspers, L, Lombardi, MS, Odekerken, JC, Burright, EN and 
Kaemmerer, WF (2008). Identiﬁcation and allele-speciﬁc silencing of the mutant 
huntingtin allele in Huntington’s disease patient-derived ﬁbroblasts. Hum Gene Ther 
19: 710–719.
26. Zhang, S, Feany, MB, Saraswati, S, Littleton, JT and Perrimon, N (2009). Inactivation 
of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of 
a Huntington’s disease model. Dis Model Mech 2: 247–266.
27. Lombardi, MS, Jaspers, L, Spronkmans, C, Gellera, C, Taroni, F, Di Maria, E et al. 
(2009). A majority of Huntington’s disease patients may be treatable by individualized 
allele-speciﬁc RNA interference. Exp Neurol 217: 312–319.
28. Pﬁster, EL, Kennington, L, Straubhaar, J, Wagh, S, Liu, W, DiFiglia, M et al. (2009). Five 
siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s 
disease patients. Curr Biol 19: 774–778.
29. Hu, J, Liu, J and Corey, DR (2010). Allele-selective inhibition of huntingtin expression 
by switching to an miRNA-like RNAi mechanism. Chem Biol 17: 1183–1188.
30. Hu, J, Matsui, M, Gagnon, KT, Schwartz, JC, Gabillet, S, Arar, K et al. (2009). Allele-
speciﬁc silencing of mutant huntingtin and ataxin-3 genes by targeting expanded 
CAG repeats in mRNAs. Nat Biotechnol 27: 478–484.
31. Pﬁster, EL and Zamore, PD (2009). Huntington’s disease: silencing a brutal killer. 
Exp Neurol 220: 226–229.
32. Gagnon, KT, Pendergraff, HM, Deleavey, GF, Swayze, EE, Potier, P, Randolph, J et al. 
(2010). Allele-selective inhibition of mutant huntingtin expression with antisense 
oligonucleotides targeting the expanded CAG repeat. Biochemistry 49: 10166–10178.
33. Warby, SC, Montpetit, A, Hayden, AR, Carroll, JB, Butland, SL, Visscher, H et al. (2009). 
CAG expansion in the Huntington disease gene is associated with a speciﬁc and 
targetable predisposing haplogroup. Am J Hum Genet 84: 351–366.
34. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular 
mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev 
Pharmacol Toxicol 50: 259–293.
35. Monia, BP, Johnston, JF, Ecker, DJ, Zounes, MA, Lima, WF and Freier, SM (1992). 
Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. 
J Biol Chem 267: 19954–19962.
36. Smith, RA, Miller, TM, Yamanaka, K, Monia, BP, Condon, TP, Hung, G et al. (2006). 
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116: 
2290–2296.
37. Lima, WF, Rose, JB, Nichols, JG, Wu, H, Migawa, MT, Wyrzykiewicz, TK et al. (2007). 
Human RNase H1 discriminates between subtle variations in the structure of the 
heteroduplex substrate. Mol Pharmacol 71: 83–91.
38. Slow, EJ, van Raamsdonk, J, Rogers, D, Coleman, SH, Graham, RK, Deng, Y et al. 
(2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington 
disease. Hum Mol Genet 12: 1555–1567.
39. Hodgson, JG, Smith, DJ, McCutcheon, K, Koide, HB, Nishiyama, K, Dinulos, MB et al. 
(1996). Human huntingtin derived from YAC transgenes compensates for loss of 
murine huntingtin by rescue of the embryonic lethal phenotype. Hum Mol Genet 5: 
1875–1885.
40. Gray, M, Shirasaki, DI, Cepeda, C, André, VM, Wilburn, B, Lu, XH et al. (2008). 
Full-length human mutant huntingtin with a stable polyglutamine repeat can 
elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 
6182–6195.
41. Seth, PP, Siwkowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2009). 
Short antisense oligonucleotides with novel 2’-4’ conformationaly restricted 
nucleoside analogues show improved potency without increased toxicity in animals. 
J Med Chem 52: 10–13.
42. Crooke, ST (2008). Antisense Drug Technology. Principles, Strategies, and Applications. 
CRC Press: Boca Raton, FL.
43. Takahashi, M, Watanabe, S, Murata, M, Furuya, H, Kanazawa, I, Wada, K et al. (2010). 
Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl 
Acad Sci USA 107: 21731–21736.
44. Liu, W, Kennington, LA, Rosas, HD, Hersch, S, Cha, JH, Zamore, PD et al. (2008). 
Linking SNPs to CAG repeat length in Huntington’s disease patients. Nat Methods 5: 
951–953.
45. Pangalos, MN, Schechter, LE and Hurko, O (2007). Drug development for CNS 
disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 
521–532.
46. Vonsattel, JP, Myers, RH, Stevens, TJ, Ferrante, RJ, Bird, ED and Richardson, EP Jr 
(1985). Neuropathological classiﬁcation of Huntington’s disease. J Neuropathol Exp 
Neurol 44: 559–577.
47. Reiner, A, Del Mar, N, Meade, CA, Yang, H, Dragatsis, I, Zeitlin, S et al. (2001). 
Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice. 
J Neurosci 21: 7608–7619.
48. Zeron, MM, Hansson, O, Chen, N, Wellington, CL, Leavitt, BR, Brundin, P et al. 
(2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity 
in a mouse model of Huntington’s disease. Neuron 33: 849–860.
